A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

PHASE3TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 8, 2019

Primary Completion Date

June 29, 2020

Study Completion Date

June 29, 2020

Conditions
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Interventions
DRUG

macitentan 10 mg

macitentan 10 mg, film-coated tablet, oral use

Trial Locations (23)

814-8522

Fukuoka University Nishijin Hospital, Fukuoka

960-1247

Fukushima Medical University Hospital, Fukushima

890-8520

Kagoshima University Hospital, Kagoshima

634-8522

Nara Medical University Hospital, Kashihara

802-8555

Kokura Kinen Hospital, Kitakyushu

650-0017

Kobe University Hospital, Kobe

360-0197

Saitama Cardiovascular and Respiratory Center, Kumagaya

737-8505

Kure Kyosai Hospital, Kure

830-0011

Kurume University Hospital, Kurume

153-8515

Toho University Ohashi Medical Center, Meguro-ku

108-8329

IIUHW Mita Hospital, Minatoku

181-8611

Kyorin University Hospital, Mitaka

852-8501

Nagasaki University Hospital, Nagasaki

701-1192

National Hospital Organization Okayama Medical Center, Okayama

060-8543

Sapporo Medical University Hospital, Sapporo

060-8648

Hokkaido University Hospital, Sapporo

857-8511

Sasebo City General Hospital, Sasebo

160-0016

Keio University Hospital, Shinjuku-ku

565-8565

National Cerebral and Cardiovascular Center Hospital, Suita

514-8507

Mie University Hospital, Tsu

305-8576

University of Tsukuba Hospital, Tsukuba

990-0828

Yamagata University Hospital, Yamagata

236-0004

Yokohama City University Hospital, Yokohama

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

EPS Corporation

OTHER

collaborator

Imepro Inc.

UNKNOWN

collaborator

General Laboratory, BML, Inc.

UNKNOWN

collaborator

Mitsubishi Logistics Corporation

UNKNOWN

lead

Actelion

INDUSTRY